NCT01354353View on ClinicalTrials.gov

A Study of Safety and Tolerability in Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Schizophrenia
Interventions
DRUG

LY2140023

Administered orally

DRUG

Aripiprazole

Administered orally

Trial Locations (2)

91206

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale

92845

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Garden Grove

Sponsors
All Listed Sponsors
lead

Denovo Biopharma LLC

INDUSTRY

NCT01354353 - A Study of Safety and Tolerability in Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter